Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study

BACKGROUND: A recently registered device containing 80 mg of adalimumab (ADA) allows an alternative dose escalation regimen with ADA 80 mg every other week (EOW) given as a single subcutaneous injection instead of 40 mg every week. The ADASCAL study evaluated the preferences and satisfaction of infl...

Descripción completa

Detalles Bibliográficos
Autores principales: Taxonera, Carlos, Martínez-Montiel, María Pilar, Barreiro-de-Acosta, Manuel, Vera, Isabel, Lorente, Rufo, Vega, Pablo, Diz-Lois, María Teresa, Fuentes Coronel, Ana María, Pérez Calle, José Lázaro, Casis, Begoña, Ferreiro-Iglesias, Rocío, Calvo, Marta, Olivares, David, Alba, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804976/
https://www.ncbi.nlm.nih.gov/pubmed/35116079
http://dx.doi.org/10.1177/17562848211056157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804976/
https://www.ncbi.nlm.nih.gov/pubmed/35116079
http://dx.doi.org/10.1177/17562848211056157

Ejemplares similares